CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 2
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)
CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR
#EGFR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 32%임상시험 3상태 ACTIVE